Coya Therapeutics, Inc.
COYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4 | $6 | $0 | $0 |
| % Growth | -40.8% | – | – | – |
| Cost of Goods Sold | $12 | $6 | $4 | $0 |
| Gross Profit | -$8 | $1 | -$4 | $0 |
| % Margin | -233.9% | 8.3% | – | – |
| R&D Expenses | $12 | $6 | $5 | $3 |
| G&A Expenses | $9 | $8 | $5 | $2 |
| SG&A Expenses | $9 | $8 | $5 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$12 | -$5 | -$4 | $0 |
| Operating Expenses | $9 | $8 | $5 | $5 |
| Operating Income | -$17 | -$8 | -$10 | -$5 |
| % Margin | -485.4% | -131.7% | – | – |
| Other Income/Exp. Net | $2 | $1 | -$2 | -$0 |
| Pre-Tax Income | -$16 | -$7 | -$12 | -$5 |
| Tax Expense | -$1 | $1 | $0 | $0 |
| Net Income | -$15 | -$8 | -$12 | -$5 |
| % Margin | -418.7% | -133.1% | – | – |
| EPS | -0.98 | -0.79 | -1.231 | -0.74 |
| % Growth | -24.1% | 35.8% | -66.3% | – |
| EPS Diluted | -0.98 | -0.79 | -1.231 | -0.74 |
| Weighted Avg Shares Out | 15 | 10 | 10 | 7 |
| Weighted Avg Shares Out Dil | 15 | 10 | 10 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$17 | -$7 | -$9 | -$5 |
| % Margin | -483.9% | -122.2% | – | – |